Nexalin Technology Files S-1/A Amendment

TL;DR

Nexalin Tech filed an S-1/A on Jan 30, 2025. Still working on registering shares.

AI Summary

Nexalin Technology, Inc. filed an S-1/A amendment on January 30, 2025, for its registration statement. The company, incorporated in Delaware with its principal executive offices in Houston, TX, is in the electromedical and electrotherapeutic apparatus industry. This filing is an amendment to a previous registration statement (No. 333-283960) and indicates ongoing efforts to register securities.

Why It Matters

This S-1/A filing signifies Nexalin Technology's continued efforts to register securities with the SEC, which is a necessary step before they can be offered to the public.

Risk Assessment

Risk Level: medium — S-1/A filings often indicate a company is preparing to go public or raise capital, which carries inherent market and execution risks.

Key Numbers

• 333-283960 — SEC File Number (Identifies the specific registration filing)
• 25574867 — Film Number (Internal SEC processing number)

Key Players & Entities

• Nexalin Technology, Inc. (company) — Registrant
• 333-283960 (registration_number) — SEC Registration Number
• January 30, 2025 (date) — Filing Date
• Mark White (person) — Chief Executive Officer
• Martin S. Siegel (person) — Legal Counsel

FAQ

Key Financial Figures

• $0.001 — ares”) of common stock, par value $0.001 per share of Nexalin Technology, Inc. (
• $2.60 — Capital Market on January 29, 2025 was $2.60 per share. We are an “emerging

Filing Documents

• nexalintech_s1a2.htm (S-1/A) — 452KB
• nexalintech_ex5-1.htm (EX-5.1) — 12KB
• nexalintech_ex23-1.htm (EX-23.1) — 3KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• img_001.jpg (GRAPHIC) — 11KB
• 0001829126-25-000571.txt ( ) — 489KB

Use of Proceeds

Use of Proceeds 29 Dividend Policy 30 September 2022 Public Offering 31 Selling Stockholders 32

Executive Compensation

Executive Compensation 34

Description of Securities

Description of Securities 38 Plan of Distribution 42 Legal Matters 44 Experts 44 Where You Can Find Additional Information 44 Incorporation of Certain Information by Reference 45 i ABOUT THIS PROSPECTUS This prospectus describes the general manner in which the Selling Stockholders may offer from time to time up to an aggregate of 2,798,613 shares of common stock, par value $0.001 per share (“Common Stock”), of Nexalin Technology, Inc. (the “Company”, “we”, “us” or “our”), consisting of (i) up to 347,250 shares of Common Stock issuable upon the exercise of the common stock purchase warrant that was issued to Maxim Partners, LLC (“Maxim Partners”) as compensation for its services in connection with the Company’s 2022 initial public offering; (ii) up to 2,315,000 shares of Common Stock issuable upon the exercise of the common stock purchase warrants issued to purchasers of Units (containing both a share of common stock and a common stock purchase warrant) in connection the Company’s 2022 public offering; and (iii) 136,363 shares of Common Stock issued to Maxim Partners pursuant to a renewal of its engagement agreement with the Company. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer to purchase, the shares of Common Stock offered by this prospectus, any prospectus supplement or amendments thereto if any jurisdiction to or from

View Full Filing

View this S-1/A filing on SEC EDGAR